ACTG Publications

TitleAuthorsDateJournalIssueVolume
Blinded, multicenter comparison of methods to detect a drug-resistant mutant of human immunodeficiency virus type 1 at low frequency.Halvas, Elias K ; Aldrovandi, Grace M ; Balfe, Peter ; Beck, Ingrid A ; Boltz, Valerie F ; Coffin, John M ; Frenkel, Lisa M ; Hazelwood, J Darren ; Johnson, Victoria A ; Kearney, Mary ; Kovacs, Andrea ; Kuritzkes, Daniel R ; Metzner, Karin J ; Nissley, Dwight V ; Nowicki, Marek ; Palmer, Sarah ; Ziermann, Rainer ; Zhao, Richard Y ; Jenning2006 JulJ Clin Microbiol744
Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral Therapy.Gay, Cynthia L ; Bosch, Ronald J ; Ritz, Justin ; Hataye, Jason M ; Aga, Evgenia ; Tressler, Randall L ; Mason, Stephen W ; Hwang, Carey K ; Grasela, Dennis M ; Ray, Neelanjana ; Cyktor, Josh C ; Coffin, John M ; Acosta, Edward P ; Koup, Richard A ; Mellors, John W ; Eron, Joseph J ; AIDS Clinical Trials 5326 Study Team2017 Jun 01J Infect Dis11215
The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial.Gandhi, Rajesh T ; Zheng, Lu ; Bosch, Ronald J ; Chan, Ellen S ; Margolis, David M ; Read, Sarah ; Kallungal, Beatrice ; Palmer, Sarah ; Medvik, Kathy ; Lederman, Michael M ; Alatrakchi, Nadia ; Jacobson, Jeffrey M ; Wiegand, Ann ; Kearney, Mary ; Coffin, John M ; Mellors, John W ; Eron, Joseph J ; AIDS Clinical Trials Group A5244 team2010PLoS Med87
Low frequency nonnucleoside reverse-transcriptase inhibitor-resistant variants contribute to failure of efavirenz-containing regimens in treatment- experienced patients.Halvas, Elias K ; Wiegand, Ann ; Boltz, Valerie F ; Kearney, Mary ; Nissley, Dwight ; Wantman, Michael ; Hammer, Scott M ; Palmer, Sarah ; Vaida, Florin ; Coffin, John M ; Mellors, John W2010 MarJ Infect Dis5201
Low-frequency nevirapine (NVP)-resistant HIV-1 variants are not associated with failure of antiretroviral therapy in women without prior exposure to single-dose NVP.Boltz, Valerie F ; Bao, Yajing ; Lockman, Shahin ; Halvas, Elias K ; Kearney, Mary F ; McIntyre, James A ; Schooley, Robert T ; Hughes, Michael D ; Coffin, John M ; Mellors, John W ; OCTANE/A5208 Team2014 Mar 1J Infect Dis5209
Origin of Rebound Plasma HIV Includes Cells with Identical Proviruses That Are Transcriptionally Active before Stopping of Antiretroviral Therapy.Kearney, Mary F ; Wiegand, Ann ; Shao, Wei ; Coffin, John M ; Mellors, John W ; Lederman, Michael ; Gandhi, Rajesh T ; Keele, Brandon F ; Li, Jonathan Z2016 FebJ Virol390
Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes.Wilkin, Timothy J ; McKinnon, John E ; DiRienzo, A Gregory ; Mollan, Katie ; Fletcher, Courtney V ; Margolis, David M ; Bastow, Barbara ; Thal, Gary ; Woodward, William ; Godfrey, Catherine ; Wiegand, Ann ; Maldarelli, Frank ; Palmer, Sarah ; Coffin, John M ; Mellors, John W ; Swindells, Susan2009 Mar 15J Infect Dis6199
Role of low-frequency HIV-1 variants in failure of nevirapine-containing antiviral therapy in women previously exposed to single-dose nevirapine.Boltz, Valerie F ; Zheng, Yu ; Lockman, Shahin ; Hong, Feiyu ; Halvas, Elias K ; McIntyre, James ; Currier, Judith S ; Chibowa, Margret C ; Kanyama, Cecelia ; Nair, Apsara ; Owino-Ong'or, Willis ; Hughes, Michael ; Coffin, John M ; Mellors, John W2011 May 31Proc Natl Acad Sci U S A22108
Selection and persistence of non-nucleoside reverse transcriptase inhibitor-resistant HIV-1 in patients starting and stopping non-nucleoside therapy.Palmer, Sarah ; Boltz, Valerie ; Maldarelli, Frank ; Kearney, Mary ; Halvas, Elias K ; Rock, Diane ; Falloon, Judith ; Davey, Richard T ; Dewar, Robin L ; Metcalf, Julia A ; Mellors, John W ; Coffin, John M2006 Mar 21AIDS520